Boardroom Media (CFO News)
At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top San Francisco based CFO’ operating in the Biotechnology space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Christine A. Tsingos
EVP & CFO of Bio-Rad Laboratories
Ms. Christine A. Tsingos is Chief Financial Officer, Executive Vice President of Bio Rad Laboratories Inc. Previously, she was the Chief Operating Officer and Chief Financial Officer at Attest Systems, Inc., a provider of information technology asset discovery and management tools, from August 2002 to November 2002. Prior to that, Ms. Tsingos was a consultant to Attest Systems, Inc. from October 2000 to July 2002. She was the Chief Financial Officer at Tavolo, Inc., an online retailer of gourmet cookware and food, from November 1999 to September 2000, and she was Treasurer, and later Vice President and Treasurer, of Autodesk, Inc., a developer of design software, from May 1990 to November 1999.
Follow Christine A. Tsingos:
About Bio-Rad Laboratories: Bio-Rad Laboratories has played a leading role in the advancement of scientific discovery for over 50 years by providing a broad range of
Gerard van Hamel Platerink
Chief Financial Officer of Genalyte
Board Member at HealthMine, MedAvail Technologies & Genalyte.
Follow Gerard van Hamel Platerink:
About Accuitive Medical Ventures, Genalyte, Redmile Group: Genalyte is a life sciences company developing and commercializing innovative next-generation multiplexing technology.
Shaun Holt
CFO of Berkeley Lights
Shaun joined Berkeley Lights in November 2015 and was appointed Chief Financial Officer in March 2016. Prior to becoming CFO, Shaun was Vice President of Finance. Prior to joining Berkeley Lights, Shaun spent 7 ½ years at Illumina, Inc. heading up various aspects of their Finance organization. His roles included Sr. Director, Global Head of R&D and Business Unit Finance, EMEA Head of Finance, Accounting and Facilities, and Commercial FP&A. He earned a B.S. in Finance from California State University, Stanislaus.
Follow Shaun Holt:
About Berkeley Lights: Berkeley Lights is a provider of research and development services using micro-droplet technology that change the biological processes.
Georgia Erbez
Chief Financial Officer of Harpoon Therapeutics
Georgia Erbez currently works as the Chief Financial Officer for Harpoon Therapeutics. She previously worked at Artelo Biosciences, Inc. as the Member Board Of Directors.
Follow Georgia Erbez:
About Harpoon Therapeutics: Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of cancer.
Howard Horn
CFO of Vir Biotechnology
Howard Horn is the Chief Financial Officer of VIR. Previously, he led the Financial Planning and Corporate Finance functions at Biogen. Prior to joining Biogen, he held positions of increasing responsibility and was focused on the life sciences as a consultant with McKinsey & Company and as an equity research analyst at UBS. Howard holds an M.B.A from the Wharton School of the University of Pennsylvania and a B.A in Economics from Princeton University.
Follow Howard Horn:
About Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases.
Enakshi Singh
Chief Financial Officer of Zymergen
Prior to joining Zymergen, Ena was focused on semiconductor investments at Mubadala, Abu Dhabi’s sovereign wealth fund. She spent the previous seven years in investment banking, initially at Salomon Smith Barney’s Latin America Group, later working for Merrill Lynch’s Technology Investment Banking Group. Ena studied at Cornell University and received her graduate degree at MIT Sloan School of Management.
Follow Enakshi Singh:
About Zymergen: Zymergen is a biotechnology company that specializes in machine learning, big data, and artificial intelligence.
Glenn S. Boehnlein
Chief Financial Officer & Vice President of Stryker
Follow Glenn S. Boehnlein:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Susan M. Kanaya
Senior Vice President, Finance, Chief Financial Officer and Secretary of ChemoCentryx
Ms. Susan M. Kanaya has served as our Senior Vice President, Finance, and Chief Financial Officer since January 2006, and Secretary since February 2006. Prior to joining us, Ms. Kanaya served as Senior Vice President, Finance, and Chief Financial Officer at Kosan Biosciences Inc., a biotechnology company, from 1999 to 2005. Prior to this, she served in financial management positions at SUGEN, Inc., a biotechnology company, from 1994 to 1999, most recently as Vice President, Finance, and Treasurer. Ms. Kanaya also served as Controller with high technology companies and as a public accountant with KPMG. Ms. Kanaya received her B.S. in business administration from the University of California, Berkeley.
Follow Susan M. Kanaya:
About ChemoCentryx: ChemoCentryx develops orally administered small molecule therapeutics that target chemokine receptors and related chemo-attractants.
Bryan Giraudo
Chief Financial Officer & COO of Gossamer Bio
Mr. Giraudo is the Chief Financial Officer of Gossamer Bio. Previously, he was Senior Managing Director at LEERINK Partners, where he was responsible for LEERINK’s Western North America and Asia life sciences investment banking practice. Prior to joining LEERINK Partners in 2009, Bryan was a Managing Director in Merrill Lynch’s Global Healthcare Investment Banking Group. Bryan received his B.A. from Georgetown University.
Follow Bryan Giraudo:
About Gossamer Bio: Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.
Martyn Ansell
Chief Financial Officer and Vice President, Finance of Molecular Devices
Martyn joined Molecular Devices in June 2012 as Vice President, Finance. Prior to joining Molecular Devices he was Chief Financial Officer of Vistec Semiconductor Systems, a global leader in the development and manufacture of electron-beam lithography equipment for the semiconductor industry. Prior to joining Vistec, Martyn spent over 12 years at Applied Materials, a manufacturer of semiconductor equipment, where he held a number of senior financial management positions in business development and within several product divisions. In addition, he has held positions at Coopers & Lybrand, in San Jose, California and Ernst & Young in the U.K. Martyn received a BA in Accounting and Finance with Honors from the Manchester Metropolitan University, Manchester, England and is a member of the American Institute of Certified Public Accountants.
Follow Martyn Ansell:
About Molecular Devices: Bioanalytical Systems and Solutions
Judy Koh
Managing Director/Chief Financial Officer of Bay City Capital
Judy Koh, MBA, CPA, is an Operating Partner and the Chief Financial Officer at Bay City Capital and has been with the firm since April 1998.
Follow Judy Koh:
About Bay City Capital, Illumina Ventures: Bay City Capital LLC (Bay City Capital), established in 1997 , specializes in investments in the life sciences industry.
Paul Manners
Chief Financial Officer of Trak
Follow Paul Manners:
About Trak: Sandstone Diagnostics provides an integrated wellness technology that empowers consumers to measure, monitor, and improve their health.
Nathan Weems
Chief Financial Officer of VitalConnect
Nathan has accrued over 13 years of operational excellence in management roles spanning finance, business development, and marketing, most recently serving as Sr. Director of Finance at Natera, a public Bay Area biotech company. Earlier experience includes tenure at a top Wall Street investment bank and Big-4 accounting firm. Nathan brings expertise in accounting, due diligence, market research, fund raising and investor relations. He holds a BA from the University of Southern California and an MBA from Wharton. When his HP 12C is not within reach, you can usually find Nathan on two wheels or two skis exploring the outdoors with his family.
Follow Nathan Weems:
About VitalConnect: VitalConnect is a wearable biosensor technology for wireless hospital and remote patient monitoring.
Vikram Jog
CFO of Fluidigm
Vikram Jog has served as our Chief Financial Officer since February 2008. From April 2005 to February 2008, Mr. Jog served as Chief Financial Officer for XDx, Inc., a molecular diagnostics company. From March 2003 to April 2005, Mr. Jog was a Vice President of Applera Corporation and Vice President of Finance for its related businesses, Celera Genomics and Celera Diagnostics. From April 2001 to March 2003, Mr. Jog was Vice President of Finance for Celera Diagnostics and Corporate Controller of Applera Corporation. Mr. Jog holds a Bachelor of Commerce degree from Delhi University and an M.B.A. from Temple University. Mr. Jog is a member of the American Institute of Certified Public Accountants.
Follow Vikram Jog:
About Fluidigm: Fluidigm is a biotech tools company that creates microfluidic-based chips and instrumentation for biological research.
Tom O’Neil
Chief Financial Officer of Protagonist Therapeutics
Tom O’Neil is the chief financial officer of [Arcadia Biosciences](https://www.crunchbase.com/organization/arcadia-biosciences#/entity), an agricultural technology company focused on developing products that benefit the environment and human health. Prior to that, he held the same position at Sorbent Therapeutics. O’Neil has also served as the vice president of finance and marketing at ChemGenex Pharmaceuticals and as a team member at HX Diagnostics. O’Neil holds a bachelor’s degree in international relations from Pomona College and master’s degree in business administration from the University of California, Los Angeles. He lives in San Francisco, California, United States.
Follow Tom O’Neil:
About Nodality, Protagonist Therapeutics: Protagonist Therapeutics develops orally-stable peptides to treat diseases that are currently addressed by injectable antibodies.
Christopher Senner
Executive Vice President and Chief Financial Officer of Exelixis
Chris Senner is Executive Vice President and Chief Financial Officer at Exelixis. Since July 2015, Mr. Senner has held this role with responsibility for ensuring the prudent management of the company’s assets, allowing Exelixis to invest in its proprietary and partnered molecules, launch new indications and otherwise advance its important work in the treatment of cancer. Prior to joining Exelixis, Mr. Senner served as Vice President, Corporate Finance at Gilead Sciences, Inc., which he joined in March 2010. At Gilead, he was accountable for controllership, tax, treasury and corporate and operational financial planning. Before joining Gilead, Mr. Senner spent 18 years at Wyeth in a variety of financial roles with increasing responsibility, most notably as Chief Financial Officer of Wyeth’s U.S. pharmaceuticals business and the BioPharma business unit. Mr. Senner holds a B.S. in Finance from Bentley College.
Follow Christopher Senner:
About Exelixis: Exelixis works is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases.
McDavid Stilwell
Chief Financial Officer of Coherus Biosciences
McDavid Stilwell is the Chief Financial Officer at Coherus BioSciences.
Follow McDavid Stilwell:
About Coherus Biosciences: Coherus Biosciences develops, manufactures, and commercializes biologic therapeutics for oncology and inflammatory diseases.
Jeffrey H. Cooper
Chief Financial Officer of Humanigen
Follow Jeffrey H. Cooper:
About Humanigen, Sierra Oncology: Humanigen is a biopharmaceutical company that focuses on developing human antibody therapeutics.
John Beck
Acting Chief Financial Officer of AEGEA Medical
John started BeckCFO in 2007 and brings over 30 years of experience in financial management, strategic planning and execution for technology firms. John has worked with early stage companies in life sciences (medical device and pharmaceutical), fabless semiconductor, software and software as a service, hardware systems, and services. John has held full-time CFO positions with both public and private companies, and, in addition to finance, has broad experience managing cross-functional areas such as IP management, legal, treasury, risk management, HR, IT and facilities. John’s background also includes managing the accounting, finance and reporting requirements of European and Asian offices. Before starting BeckCFO, John previously served as CFO for several companies including: Silicon Bandwidth, Inc., nDSP Corporation (acquired by PixelWorks), Sigma Designs, Inc., Augeo Software, Meta-Software, Inc. (acquired by Synopsys), Sellectek Incorporated, RayLAN Corporation, Optimem and Spectra Logic subsidiaries of Cipher Data Products, and Minton Company. Prior to his tenure at technology firms, John held senior audit positions at Ernst & Young and KPMG Peat Marwick certified public accounting firms. John earned a B.S. degree in Commerce with an Accounting emphasis, cum laude, from Santa Clara University. He is also a licensed C.P.A. (inactive), with the State of California.
Follow John Beck:
About AEGEA Medical, CloudPhysics: AEGEA Medical manufactures surgical and medical instruments.
Scott Gorton
CFO of Apton Biosystems
Follow Scott Gorton:
About Apton Biosystems, Cloudleaf, Precursor Energetics: Apton Biosystems develops a high-throughput and low-cost sequencing platform that revolutionizes the availability of genetic analysis.
Ryan Martins
Chief Financial Officer of 89bio
Ryan Martins is chief financial officer at 89bio.
Follow Ryan Martins:
About 89bio: 89Bio is a biopharmaceutical company building a pipeline of biologic and small molecule treatments for liver and metabolic disorders.
Graham Cooper
COO, CFO of Assembly Biosciences
Graham Cooper joined us as Chief Financial Officer in February 2013. Prior to joining us, during 2012, Graham Cooper was the Executive Vice President, Finance and Chief Financial Officer of Geron Corporation, a biopharmaceutical company focused on cancer therapies. From 2006 until 2011, Graham Cooper served as Senior Vice President, Chief Financial Officer and Treasurer of Orexigen Therapeutics, Inc., a biotechnology company focused on obesity. From 1999 to 2006, Graham Cooper held positions of increasing responsibility including Director, Health Care Investment Banking, at Deutsche Bank Securities, where he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field. From August 1992 to January 1995, he worked as an accountant at Deloitte & Touche, and was previously a C.P.A. Graham Cooper holds a B.A. in Economics from the University of California at Berkeley and an M.B.A. from the Stanford Graduate School of Business.
Follow Graham Cooper:
About Assembly Biosciences, Beam Therapeutics: Assembly Biosciences, Inc. is a public biotechnology company and provider of oral biologic therapeutics.
John Borgeson
Chief Financial Officer of ALX Oncology
John Borgeson is our Chief Financial Officer and has served in this position since June 2014. Borgeson brings over 25 years of pharmaceutical industry experience in finance, strategy and operations on a global scale. Previously Borgeson was a Vice President of Finance at Pfizer and a member of Pfizer’s Global Financial Leadership Team. Borgeson’s roles at Pfizer included CFO for Pfizer’s biotherapeutics division and corporate tax executive with responsibility for US and Europe. Under Borgeson’s leadership, Pfizer completed a transformational restructuring of the global tax group that was replicated by other Fortune 50 companies. Borgeson has more recently led finance for a variety of private biotech companies, including Labrys Biologics, which was acquired by Teva Pharmaceuticals for $825 million. He was also CFO of venBio, a venture capital firm with a strong track record in biotechnology investing. Borgeson started his career as an auditor with Ernst & Young and is a certified public accountant. He has an M.B.A. from R.I.T. and an undergraduate degree from the School of Management at the University at Buffalo (S.U.N.Y.).
Follow John Borgeson:
About ALX Oncology, Kodiak Sciences: ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Anthony M. Rimac
Chief Financial Officer of Cognoa
Follow Anthony M. Rimac:
About Cognoa: Cognoa is a behavioral health company focused on improving the lives and outcomes of children and families living with behavioral conditions
Anurag Goel
CFO, Board Of Directors & Investor of Celltheon
Anurag Goel is the CFO/Business Development/Board Of Directors at Celltheon.
Follow Anurag Goel:
About Afferent Technologies, Celltheon: Celltheon is a cell line development and expression technologies company.
Steve Krognes
CFO of Denali Therapeutics
Mr. Steve Krognes serves as Senior Vice President, Regional Head of Finance and IT and Chief Financial Officer of Pharma North America at Genentech, Inc. Mr. Krognes joined Roche in January 2004 as global head of Mergers and Acquisitions. He served as Head of Corporate Finance-Corporate Development of Roche Holding AG. In this role, he led Roche’s internal Mergers and Acquisitions group and was responsible for all Roche transactions worldwide. Prior to joining Roche Holding AG, Mr. Krognes worked as a venture capitalist in Scandinavia, as a mergers and acquisitions investment banker with Goldman Sachs and Danske Bank, and as a management consultant with McKinsey & Co. He has been a Director of California Healthcare Institute since August 2010. He is a second lieutenant in the Royal Norwegian Air Force. Mr. Krognes holds a Master’s in Business Administration from the Harvard Business School and a Bachelor’s in Economics from the Wharton School at the University of Pennsylvania.
Follow Steve Krognes:
About California Healthcare Institute, Denali Therapeutics: Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.
Eric d’Esparbes
Senior Vice President & Chief Financial Officer of Innoviva
Eric d’Esparbes is SVP and CFO at Innoviva. From 2010 to 2014, Mr. d’Esparbes served as the Chief Financial Officer of Joule Unlimited, a biotechnology company. Prior to Joule Unlimited, he was the Vice President, Finance, of AEI, a global emerging markets energy company. Eric arned a BAA in International Finance from the University of Montreal’s Hautes Etudes Commerciales in Montreal, Canada.
Follow Eric d’Esparbes:
About Innoviva: Innoviva is committed to building long-lasting value and improving patient care.
Mike Anthofer
CFO Consultant of Murdock Martell, Inc
Mike Anthofer is the CFO Consultant of Murdock Martell.
Follow Mike Anthofer:
About Mojo Networks, Murdock Martell, Inc: Specialized finance, accounting and HR solutions on demand
Michael Farrow
CFO of PipelineRx
Mr. Farrow is a seasoned Financial leader with over 20 years of experience driving improved financial performance across a wide range of industries. Prior to joining PipelineRx, Mike served as a CFO for CloudMade, a leader in location based technologies working with the world’s leading automotive and consumer electronics OEMs. Previously, he served as CFO for leading digital media companies NetShelter Technology Media and Jumpstart Automotive Media which deliver internet advertising across technology and automotive-related websites, respectively. He was also the top Financial Manager for fastest growing division at EarthLink, a Fortune 1000 company. Mr. Farrow earned a B.S. in Finance from the University of Arizona and has his M.B.A. from the USC Marshall School of Business.
Follow Michael Farrow:
About PipelineRx: PipelineRx is a clinical telepharmacy services company that offers clinical telepharmacist teams to its hospital clients.
Michael Byrnes
Chief Financial Officer of Effector Therapeutics
Michael Byrnes joined eFFECTOR Therapeutics as Chief Financial Officer in 2020.
Follow Michael Byrnes:
About Effector Therapeutics: Effector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.
Paul A. Stone
Chief Financial Officer & General Counsel of IDEAYA Biosciences
Stone Paul A. joined IDEAYA Biosciences as Chief Financial Officer, General Counsel in 2018.Paul A. Stone, J.D. joined 5AM Ventures in July 2009 as General Counsel and Chief Operating Officer. In addition to his legal and operational responsibilities, he serves as a Board Observer at Kinestral, Rennovia and Wildcat. Mr. Stone has held managerial and operating roles at several private and public biopharmaceutical companies. Most recently he was General Counsel and Senior VP Intellectual Property at Ethos Pharmaceuticals. Previously he was Senior VP, General Counsel, and Chief Patent Counsel at Ilypsa (acquired by Amgen). Prior to Ilypsa, he was VP, Chief Patent Counsel for Symyx (IPO in 1999). Mr. Stone received his J.D. from the University of Wisconsin Law School in 1995 and practiced as a Patent Attorney at Senniger, Powers, Leavitt & Roedel. He taught patent law, trade secrets law and licensing as an adjunct professor at the University of Missouri and Santa Clara University.
Follow Paul A. Stone:
About 5AM Ventures, IDEAYA Biosciences: IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality
Zack McNealy
CFO of Inception Sciences
Zack McNealy joined Ventus Therapeutics as CFO in 2019.Zack McNealy is the Vice President, Finance responsible for Versant’s domestic and international management company entities. Zack also works extensively with a number of Versant’s biotech portfolio companies on their international structuring and operational setup. Zack joined Versant after spending seven years at Biotie Therapies (formerly Synosia Therapeutics) where he was Vice President, Finance supporting the U.S. and Swiss operations of the company. Prior to Biotie, Zack spent ten years at Johnson & Johnson as Plant Controller, Finance Manager and Financial Analyst. Zack received an MBA from the Wharton School, University of Pennsylvania and a BS in finance and accounting from Miami University (Ohio).
Follow Zack McNealy:
About Inception Sciences, Ventus Therapeutics: Inception Sciences creates therapies with transformative potential to address diseases and disorders with significant unmet need.
Jeet Mahal
Chief Financial and Business Officer of Jasper Therapeutics
Jeet Mahal is the Chief Financial and Business Officer at Jasper Therapeutics.
Follow Jeet Mahal:
About Jasper Therapeutics: Jasper Therapeutics is a biotechnology company focused on enabling safer conditioning and therapeutic.
Andrew A. Sauter
Chief Financial Officer of Lifemax
Follow Andrew A. Sauter:
About Lifemax, LifeSci Venture Partners: Lifemax is a biotechnology company that develops therapeutics for various medical sectors.
Gordon Galloway
CFO of Vali Nanomedical
Gordon Galloway received his MBA from the UCLA Anderson School of Management and his BSBA from the UC Berkeley Haas School of Business. Of nine years working in finance, he spent three in banking and two at Stryker Corporation, a Fortune 500 manufacturer and technology leader in the medical device industry. At Stryker, he helped support the acquisition of two entrepreneurial startups in order to commercialize cutting-edge health care technology around the world. He has worked alongside Dr. Gray on a variety of projects for over a decade, and became Vali’s CFO in 2014.
Follow Gordon Galloway:
About Vali Nanomedical: Vali is a biotechnology company founded in 2013.
